Progressive Dental Care Dentist Medicare: Not Enrolled in Medicare Practice Location: 112 East Main Strreet, Boyne City, MI 49712 Phone: 231-582-6944 Fax: 231-582-6978 |
Park View Family Dentistry Dentist Medicare: Not Enrolled in Medicare Practice Location: 202 N Lake St, Boyne City, MI 49712 Phone: 231-582-4480 Fax: 231-582-4460 |
Michael A. Fleming D.d.s., P.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 830 State St, Boyne City, MI 49712 Phone: 231-582-8000 |
Boyne City Dental Dentist Medicare: Not Enrolled in Medicare Practice Location: 830 State St, Boyne City, MI 49712 Phone: 231-582-6644 Fax: 231-582-6853 |
Boyne Lakeview Dental P.l.l.c. Dentist Medicare: Not Enrolled in Medicare Practice Location: 202 N Lake St, Boyne City, MI 49712 Phone: 231-582-7101 |
News Archive
MILabs BV has launched a complete new preclinical product line at the 2014 Annual European Association of Nuclear Medicine Meeting in Gothenburg, Sweden, October 18-22 (www.eanm.org). It consists of the new 4-series comprising U-SPECT4, U-SPECT4CT, VECTor4 and VECTor4CT incorporating significant improvements over the former PLUS-series. The 4-series carries even further the tradition of MILabs to deliver the best SPECT and PET image resolution available in the market.
Researchers from the Peninsula Medical School, the University of Cambridge and the University of Michigan, have for the first time identified a relationship between Vitamin D, the "sunshine vitamin", and cognitive impairment in a large-scale study of older people.
Pten (short for phosphatase and tensin homolog) is a tumor suppressor that is defective in about 20-25 percent of all patients with cancers. Mayo Clinic researchers now have discovered that Pten safeguards against tumor formation by keeping chromosome numbers intact when a cell splits into two daughter cells.
Enzymes, workhorse molecules of life that underpin almost every biological process, may have a new role as "intelligent" micro- and nanomotors with applications in medicine, engineering and other fields.
Cyrenaic Pharmaceuticals Inc. a private drug development company focused on the treatment of CNS disorders, today announced Phase IIa clinical results for CYR-101, its novel investigational drug for the treatment of schizophrenia. The results from the study showed that the drug alleviated the symptoms of the disease, including the negative and cognitive symptoms.
› Verified 6 days ago